Clinical Trial Search

Primary: Number of Subjects With Any Solicited Local and General Symptoms — 15; 16; 4; 10 Subjects

Primary: Number of Participants With Solicited Adverse Reactions — 507; 480 Count of Participants

Primary: Anti-PRP IgG Geometric Mean Concentration (GMC) — 0.40; 0.41 μg/mL — p=0.85

Primary: Number of Subjects With Anti-polyribosyl Ribitol Phosphate (Anti-PRP) Antibody Concentrations Greater Than or Equal to 1 Milligram Per Milliliter — 72; 75; 65; 66 Subjects

Primary: Change in Geometric Mean Titre Ratio, A/H1N1 Strain — 3.13; 3.17 Ratio of Day 0 and Day 21-28 titres

Primary: Geometric Mean Anti-PRP (Polyribosyl Ribitol Phosphate) Concentrations at Day 1 (4 Years Post Booster Dose Administered in Study V37_07E1) — 2.66; 5.05 Concentration in…

Primary: Seropositivity Rate (SPR) to Hepatitis A — 100; 100; 100; 100 Percentage of participants

Primary: The Number of Anti-HBs Seroprotected Participants 1 Month After the Third Dose. — 230; 226 Participants

Primary: Immunogenicity - Seroprotection (Seroconversion for Pertussis) to Each Vaccine Component — 93.1; 99.2; 98.5; 93.1 percentage of subjects

Primary: Percentage of Participants With Nasopharyngeal Carriage of Streptococcus Pneumoniae — 12.5; 7.2; 16.6; 9.3 percentage of participants

Primary: Person Year Rate as Regards Subjects With Culture-confirmed IPD Due to Any of the 10 Pneumococcal Vaccine Serotypes. In Children Starting Vaccination Within 7 Months of…

Primary: Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Micrograms Per Milliliter (µg/mL) — 292; 100…

Primary: Increase in Geometric Mean Titre Ratio, A/H1N1 Strain — 4.337; 4.702 Ratio of Day 0 and Day 21-28 titres

Primary: Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations Greater Than or Equal to (≥) 0.15 Microgram Per Milliliter (µg/mL) and ≥ 1.0…

Primary: Antibody Prevalence Rate Against Anti-PRP With 1 μg/mL or Higher, Diphtheria Toxin, Pertussis, Tetanus Toxin, and Polio Virus, Defined as the Percentage of Participants…

Primary: Anti-Polyribosyl Ribitol Phosphate (PRP) Antibody Concentrations — 10.170; 11.424; 11.438; 11.021 microgram per milliliter (µg/mL)

Primary: Antibody Concentrations Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) - Primary…

Primary: Frequency and Intensity of Local and Systemic Solicited Adverse Events, Cohort A (6 Months to Less Than 3 Years) — 254; 167; 160; 111 Participants

Primary: Age Adjusted Percentage of Participants With a Physician Visit Due to Any Diagnosis Within 30 Days of the Index Date of the Confirmed Influenza A and B Cases in the…

Primary: Number of Participants With Genotypic Resistance — 44; 1; 0; 2 participants

Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each HA-F A/Sing Product Administration — 4; 3; 7; 9 Participants

Primary: Number of Subjects Reporting at Least One Confirmed Occurrence of Influenza A or B. — 58; 128 subjects

Primary: Frequency of CD4 T Cells With a Given Functional Potential — 0.70; 0.55; 0.52; 0.38 Percentage

Primary: Number of Participants With Immediate Adverse Events — 0; 0 participants

Primary: Ratios of Geometric Mean Titer (GMT) in Subjects (6 to <48 Months Old) After Receiving Two Doses of Either TIVc or TIVe Vaccine — 7.82; 5.5; 5.93; 3.69 Ratios

Primary: Hospitalization — 26; 2 Participants

Primary: The Difference in Seroconversion/Immunogenicity Between rHA Formulated in an oil-in- Water Adjuvant (SE) Compared to a rHA Antigen Alone. — 83; 70; 9; 76 percentage of…

Primary: Summary of Influenza Seroprotection Post-vaccination With Fluzone® Vaccine. — 44; 34; 31; 74 Percentage of Participants

Primary: Immunogenicity - Geometric Mean Titer Fold Increase From Baseline — 3.5; 4.0; 4.5; 3.4 GMT fold increase

Primary: Total All-cause Hospitalizations — 197; 301 events